Clinical Trials for Residual or Recurrent Grade 2 IDH Mutant Glioma

Find clinical trials for residual or recurrent grade 2 idh mutant glioma. Discover research opportunities and treatment options in your area.

1 Active Trial Found

Showing 1 trial on this page

Page 1 of 1

Phase 3 Study of Vorasidenib (S095032/AG-881) in Asian Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 orIDH2 Mutation

NCT ID: NCT06780930

This clinical trial is studying a new treatment called vorasidenib for people with a specific type of brain tumor known as Grade 2 glioma, which has a mutation in the IDH1 or IDH2 genes. The goal i...

Recruiting

Phase: PHASE3 Type: interventional Locations: Taipei, , Taiwan, Beijing, , China +15 more

Related Conditions

Breast Cancer View clinical trials → Stroke View clinical trials → Obesity View clinical trials → Cancer View clinical trials → Healthy View clinical trials → Prostate Cancer View clinical trials →

Search All Trials Browse All Conditions